RetinalGenix Technologies Inc. RTGN

Company Overview

RetinalGenix Technologies Inc. (ticker: RTGN) is a healthcare technology and ophthalmic diagnostics company focused on retinal imaging, artificial intelligence-enabled diagnostics, and early disease detection. The company operates primarily in the medical technology and digital health sectors, with an emphasis on identifying ocular and systemic diseases through retinal scanning technologies and related diagnostic platforms. Public disclosures and company materials indicate that its business model centers on developing and commercializing retinal imaging systems, software analytics, and diagnostic services intended for use by healthcare providers and clinical practices.

The company’s primary revenue strategy has involved diagnostic technologies, intellectual property development, licensing opportunities, and clinical deployment partnerships tied to retinal imaging and disease screening applications. RetinalGenix has positioned itself around non-invasive screening and AI-supported healthcare workflows, particularly for diseases that may present detectable retinal biomarkers. The company evolved from earlier-stage healthcare technology initiatives into a more focused ophthalmic diagnostics business, although some historical operational details and commercialization milestones remain limited in independently verified public reporting. Data inconclusive based on available public sources regarding the scale of recurring commercial revenue and long-term market penetration.